Journals Metabolism: Clinical and Exper...

Metabolism: Clinical and Experimental
Marco Bauzá-Thorbrügge, Milica Vujičić, Belén Chanclón, Vilborg Palsdottir, Nicolas J Pillon, Anna Benrick, Ingrid Wernstedt Asterholm
BACKGROUND: The adipocyte hormone adiponectin improves insulin sensitivity and there is an inverse correlation between adiponectin levels and type-2 diabetes risk. Previous research shows that adiponectin remodels the adipose tissue into a more efficient metabolic sink. For instance, mice that overexpress adiponectin show increased capacity for hyperplastic adipose tissue expansion as evident from smaller and metabolically more active white adipocytes. In contrast, the brown adipose tissue (BAT) of these mice looks "whiter" possibly indicating reduced metabolic activity...
October 31, 2023: Metabolism: Clinical and Experimental
Ze Chen, Li-Ping Xia, Lang Shen, Dan Xu, Yu Guo, Hui Wang
Accumulating epidemiological and experimental evidence indicates that nonalcoholic fatty liver disease (NAFLD) has an intrauterine origin. Fetuses exposed to adverse prenatal environments (e.g., maternal malnutrition and xenobiotic exposure) are more susceptible to developing NAFLD after birth. Glucocorticoids are crucial triggers of the developmental programming of fetal-origin diseases. Adverse intrauterine environments often lead to fetal overexposure to maternally derived glucocorticoids, which can program fetal hepatic lipid metabolism through epigenetic modifications...
October 30, 2023: Metabolism: Clinical and Experimental
Emilie Steinbach, Davide Masi, Agnès Ribeiro, Patricia Serradas, Tiphaine Le Roy, Karine Clément
The study of the gut microbiome holds great promise for understanding and treating metabolic diseases, as its functions and derived metabolites can influence the metabolic status of the host. While research on the fecal microbiome has provided valuable insights, it tells us only part of the story. This limitation arises from the substantial variations in microorganism distribution throughout the gastrointestinal tract due to changes in physicochemical conditions. Thus, relying solely on the fecal microbiome may not be sufficient to draw comprehensive conclusions about metabolic diseases...
October 24, 2023: Metabolism: Clinical and Experimental
Arif Muhammad Aslam, Eun Bi Ma, Joo Young Huh
Sarcopenia is a geriatric disorder characterized by a progressive decline in muscle mass and function. This disorder has been associated with a range of adverse health outcomes, including fractures, functional deterioration, and increased mortality. The pathophysiology of sarcopenia is highly complex and multifactorial, involving both genetic and environmental factors as key contributors. This review consolidates current knowledge on the genetic factors influencing the pathogenesis of sarcopenia, particularly focusing on the altered gene expression of structural and metabolic proteins, growth factors, hormones, and inflammatory cytokines...
October 21, 2023: Metabolism: Clinical and Experimental
Khanyisani Ziqubu, Phiwayinkosi V Dludla, Sihle E Mabhida, Babalwa U Jack, Susanne Keipert, Martin Jastroch, Sithandiwe E Mazibuko-Mbeje
The discovery and rejuvenation of metabolically active brown adipose tissue (BAT) in adult humans have offered a new approach to treating obesity and metabolic diseases. Beyond an accomplished role in adaptive thermogenesis, BAT secretes signaling molecules known as "batokines", which are instrumental in regulating whole-body metabolism via autocrine, paracrine, and endocrine action. In addition to the intrinsic BAT metabolite-oxidizing activity, the endocrine functions of these molecules may help to explain the association between BAT activity and a healthy systemic metabolic profile...
October 20, 2023: Metabolism: Clinical and Experimental
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I Bougioukas, Aleksandra Klisic, Nikolaos Fragakis, Manfredi Rizzo
AIMS: The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatment of type 2 diabetes mellitus (T2DM), obesity or both. METHODS: Literature search was performed through Medline (via PubMed), Cochrane Library and Scopus until August 16, 2023...
October 16, 2023: Metabolism: Clinical and Experimental
Shunichiro Tsukamoto, Toru Suzuki, Hiromichi Wakui, Tatsuki Uehara, Juri Ichikawa, Hiroshi Okuda, Kotaro Haruhara, Kengo Azushima, Eriko Abe, Shohei Tanaka, Shinya Taguchi, Keigo Hirota, Sho Kinguchi, Akio Yamashita, Tomohiko Tamura, Kouichi Tamura
BACKGROUND AND AIM: Dysregulation of angiotensin II type 1 receptor-associated protein (ATRAP) expression in cardiovascular, kidney, and adipose tissues is involved in the pathology of hypertension, cardiac hypertrophy, atherosclerosis, kidney injury, and metabolic disorders. Furthermore, ATRAP is highly expressed in bone marrow-derived immune cells; however, the functional role of immune cell ATRAP in obesity-related pathology remains unclear. Thus, we sought to identify the pathophysiological significance of immune cell ATRAP in the development of visceral obesity and obesity-related metabolic disorders using a mouse model of diet-induced obesity...
October 13, 2023: Metabolism: Clinical and Experimental
Charlene Diepenbroek, Merel Rijnsburger, Astrid A S van Irsen, Leslie Eggels, Alexandre Kisner, Ewout Foppen, Unga A Unmehopa, Chloé Berland, Sophie Dólleman, Marene Hardonk, Céline Cruciani-Guglielmacci, Rudi Faust, Rick Wenning, Clarissa M Maya-Monteiro, Andries Kalsbeek, Yeka Aponte, Serge Luquet, Mireille J Serlie, Susanne E la Fleur
BACKGROUND: Growing evidence demonstrates the role of the striatal dopamine system in the regulation of glucose metabolism. Treatment with dopamine antagonists is associated with insulin resistance and hyperglycemia, while dopamine agonists are used in treatment of diabetes mellitus type 2. The mechanism underlying striatal dopamine effects in glucose metabolism, however is not fully understood. Here, we provide mechanistic insights into the role of nucleus accumbens shell (sNAc) dopaminergic signaling in systemic glucose metabolism...
October 5, 2023: Metabolism: Clinical and Experimental
Julie A D Van, Yihan Luo, Jayne S Danska, Feihan Dai, Stacey E Alexeeff, Erica P Gunderson, Hannes Rost, Michael B Wheeler
BACKGROUND: Gestational diabetes (GDM) is a distinctive form of diabetes that first presents in pregnancy. While most women return to normoglycemia after delivery, they are nearly ten times more likely to develop type 2 diabetes than women with uncomplicated pregnancies. Current prevention strategies remain limited due to our incomplete understanding of the early underpinnings of progression. AIM: To comprehensively characterize the postpartum profiles of women shortly after a GDM pregnancy and identify key mechanisms responsible for the progression to overt type 2 diabetes using multi-dimensional approaches...
October 4, 2023: Metabolism: Clinical and Experimental
Laura Valenzuela-Vallejo, Pavlina Chrysafi, Matina Kouvari, Valentina Guatibonza-Garcia, Sophia C Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodoridis, Geltrude Mingrone, Jacob George, Christos S Mantzoros
BACKGROUND: The role of metabolic/inflammatory hormonal systems in metabolic dysfunction associated steatotic liver disease (MASLD) remains to be fully elucidated. PURPOSE: To report the levels of the novel total and H-specific growth differentiation factor-15 (GDF-15) and other established hormonal systems and to describe hormonal patterns in controls and patients with MASLD and its stages. METHODS: This is a multicenter study from two Gastroenterology-Hepatology Departments (Greece and Australia) and one Bariatric-Metabolic Surgery Department (Italy)...
September 25, 2023: Metabolism: Clinical and Experimental
Jieyu Peng, Muhan Lü, Ping Wang, Yan Peng, Xiaowei Tang
No abstract text is available yet for this article.
September 23, 2023: Metabolism: Clinical and Experimental
Menghao Huang, Yang Zhang, Jimin Park, Kushan Chowdhury, Jiazhi Xu, Alex Lu, Lu Wang, Wenjun Zhang, Burcin Ekser, Liqing Yu, X Charlie Dong
BACKGROUND & AIMS: Autophagy-related 14 (ATG14) is a key regulator of autophagy. ATG14 is also localized to lipid droplet; however, the function of ATG14 on lipid droplet remains unclear. In this study, we aimed to elucidate the role of ATG14 in lipid droplet homeostasis. METHODS: ATG14 loss-of-function and gain-of-function in lipid droplet metabolism were analyzed by fluorescence imaging in ATG14 knockdown or overexpression hepatocytes. Specific domains involved in the ATG14 targeting to lipid droplets were analyzed by deletion or site-specific mutagenesis...
September 21, 2023: Metabolism: Clinical and Experimental
Yan Tao, Jingyuan Zhao, Jilong Yin, Zixin Zhou, Huijie Li, Jinhao Zang, Tianci Wang, Yalin Wang, Chun Guo, Faliang Zhu, Shen Dai, Fuwu Wang, Hui Zhao, Haiting Mao, Fengming Liu, Lining Zhang, Qun Wang
BACKGROUND: The liver regulates metabolic balance during fasting-feeding cycle. Hepatic adaptation to fasting is precisely modulated on multiple levels. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is a negative regulator of immunity that reduces several liver pathologies, but its physiological roles in hepatic metabolism are largely unknown. METHODS: TIPE2 expression was examined in mouse liver during fasting-feeding cycle. TIPE2-knockout mice, liver-specific TIPE2-knockout mice, liver-specific TIPE2- overexpressed mice were examined for fasting blood glucose and pyruvate tolerance test...
September 15, 2023: Metabolism: Clinical and Experimental
Khaled Alabduljabbar, Carel W le Roux
Diabetes is a chronic disease that affects a vast number of individuals globally, and without optimal treatment, can lead to significant health complications. Moreover, obesity is another chronic disease with several complications, which includes type 2 diabetes. Bariatric surgery is a viable long-term choice for managing diseases such as obesity and type 2 diabetes. However, the impact of pharmacotherapy before and after surgery remains unclear. In this review, we assessed the use of pharmacotherapy in patients with obesity with or without diabetes before and after bariatric surgery, focusing on weight loss, glycemic control, and the risk of postoperative complications...
November 2023: Metabolism: Clinical and Experimental
Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki, Christos S Mantzoros
The 21st century is characterized by an increasing incidence and prevalence of obesity and the burden of its associated comorbidities, especially cardiometabolic diseases, which are reaching pandemic proportions. In the late '90s, the "black box" of adipose tissue and energy homeostasis was opened with the discovery of leptin, transforming the adipose tissue from an "inert fat-storage organ" to the largest human endocrine organ and creating the basis on which more intensified research efforts to elucidate the pathogenesis of obesity and develop novel treatments were based upon...
September 7, 2023: Metabolism: Clinical and Experimental
Tongtong Hu, Qingqing Wu, Qi Yao, Jiabin Yu, Kebing Jiang, Ying Wan, Qizhu Tang
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) has increased over the past decades. Diabetic cardiomyopathy (DCM) is the leading cause of death in T2DM patients, however, the mechanism underlying DCM remains largely unknown. Here, we aimed to investigate the role of cardiac PR-domain containing 16 (PRDM16) in T2DM. METHODS: We modeled mice with cardiac-specific deletion of Prdm16 by crossing the floxed Prdm16 mouse model with the cardiomyocyte-specific Cre transgenic mouse...
September 2023: Metabolism: Clinical and Experimental
Pegah Golabi, James M Paik, Ameeta Kumar, Reem Al Shabeeb, Kathrine E Eberly, Kenneth Cusi, Nagashree GunduRao, Zobair M Younossi
BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high among subjects with type 2 diabetes (T2D). However, the prevalence and outcomes of NAFLD among individuals with pre-diabetes (PreD) and metabolically healthy and metabolically unhealthy individuals without T2D are not known. Our aim was to assess prevalence and mortality of NAFLD among these four groups. METHODS: The Third National Health and Nutrition Examination Survey (NHANES) III (1988-1994) with mortality data (follow up to 2019) via linkage to the National Death Index was utilized...
September 2023: Metabolism: Clinical and Experimental
Eyun Song, Soon Young Hwang, Min Jeong Park, Ahreum Jang, Kyeong Jin Kim, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi
OBJECTIVE: Diabetes mellitus (DM) and sarcopenia (SP) are growing public health concerns in an aging society, which share common pathophysiological mechanisms and are associated with serious health consequences. We investigated the impact of DM and SP on all-cause and cardiovascular mortalities in a longitudinal nationwide population-based study. METHODS: The study analyzed data from the Korea National Health and Nutrition Examination Survey conducted between 2008 and 2011, including information on appendicular skeletal muscle mass data...
August 21, 2023: Metabolism: Clinical and Experimental
Shenghui Chen, Xinyu Wang, Zhening Liu, Jinghua Wang, Yanjun Guo, Qinqiu Wang, Hangkai Huang, Youming Li, Chaohui Yu, Chengfu Xu
BACKGROUND & AIMS: Olfactomedin 4 (OLFM4) is a glycoprotein that is related to obesity and insulin resistance. This study aims to investigate the role and mechanisms of OLFM4 in nonalcoholic fatty liver disease (NAFLD). APPROACH & RESULTS: OLFM4 expression levels were significantly increased in liver samples from NAFLD patients and in cellular and mouse models of NAFLD. Cell lines deficient in or overexpressing OLFM4 and Olfm4-/- mice were established to study its role in NAFLD...
August 21, 2023: Metabolism: Clinical and Experimental
Stergios A Polyzos, Ilias D Vachliotis, Christos S Mantzoros
Nonalcoholic fatty liver disease (NAFLD), sarcopenia and sarcopenic obesity (SO) are highly prevalent conditions that may coexist, especially in the aging population, without any approved pharmacologic treatment for all of them. There are multiple pathophysiologic mechanisms suggested to explain an association between NAFLD and sarcopenia or SO, including alterations in the adipokines, cytokines, hepatokines and myokines, which may interplay with other factors, such as aging, diet and physical inactivity. In clinical terms, most observational studies support an association between NAFLD and sarcopenia or SO; importantly, there are few cohort studies indicating higher mortality in patients with NAFLD and sarcopenia...
August 4, 2023: Metabolism: Clinical and Experimental
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.